CagriSema and Type 2 Diabetes: REIMAGINE 2 Explained

CagriSema is one of the most closely watched combination peptides in metabolic research today. It pairs two molecules that act on different pathways at once, and the REIMAGINE program has become a common reference point for anyone trying to understand where the science is heading. This guide walks through what CagriSema is, how the combination is put together, and why the REIMAGINE 2 work in type 2 diabetes has drawn so much attention.

What CagriSema actually is

CagriSema is a fixed combination of two peptides: cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. Amylin and GLP-1 are distinct signalling systems, so combining them lets researchers study two complementary mechanisms in a single compound rather than modelling each one in isolation. That dual-pathway design is the whole point, and it is what sets CagriSema apart from single-agonist peptides.

The two halves of the molecule

• Cagrilintide is an amylin analogue engineered for a long half-life, so it stays active far longer than native amylin.
• Semaglutide is a well-characterised GLP-1 receptor agonist that has been studied extensively on its own.

Because each half is already understood individually, CagriSema gives researchers a way to look at how the two systems behave together, which is difficult to do when the peptides are handled separately.

Why REIMAGINE 2 matters

REIMAGINE is the umbrella name used for a series of clinical research programs studying CagriSema, and REIMAGINE 2 is the arm associated with type 2 diabetes. The interest here is straightforward: type 2 diabetes involves several overlapping metabolic signals, so a compound that engages more than one pathway is a natural subject for structured investigation. Researchers following this space use the REIMAGINE naming to keep track of which questions each stage of the program is asking.

We do not report specific trial figures here, because those belong in the peer-reviewed literature and shift as new data is published. What is useful to know is the shape of the research: a dual-agonist peptide, studied in a metabolic context, with type 2 diabetes as one of the central questions.

How CagriSema fits the metabolic peptide landscape

CagriSema sits alongside a growing group of next-generation metabolic peptides. Single-target agonists came first, then dual and even triple agonists followed as researchers looked for compounds that engage more of the metabolic network at once. Understanding CagriSema makes it much easier to place newer comparisons, such as CagriSema against tirzepatide or retatrutide, into context.

Sourcing CagriSema for research in Canada

For Canadian labs and independent researchers, sourcing matters as much as the science. A reliable supplier should be transparent about identity and purity, and should be able to provide a certificate of analysis for the lot you receive. At LYFE Science every compound we carry is checked by HPLC and mass spectrometry, with a COA available per lot, so you know exactly what you are working with.

We are a Canadian supplier and ship Canada-wide by Canada Post. Shipping is a flat $25 and free on orders over $150, in neutral packaging. Orders paid before noon Eastern go out the same day, with most of Canada seeing delivery in one to three business days. We accept Interac e-Transfer and crypto, including BTC, ETH, SOL, USDC and USDT.

Key takeaways

• CagriSema combines cagrilintide (an amylin analogue) with semaglutide (a GLP-1 agonist).
• The dual-pathway design is what makes it distinct from single-agonist peptides.
• REIMAGINE 2 is the type 2 diabetes arm of the broader CagriSema research program.
• Clean sourcing, with a per-lot COA, is essential for reproducible work.

If you are building out a metabolic research line, browse our full catalogue and learn more in our peptide guide before you order.

Shop research peptides in Canada